Quinolones for brucellosis: Treating old diseases with new drugs

Clinical Microbiology and Infection

Volumn 12, Issue 9, 2006, Pages 823-825

  Pappas, G ^a   Christou, L ^a   Akritidis, N ^b   Tsianos, E V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

Brucellosis; Ciprofloxacin; Fluoroquinolones; Ofloxacin; Quinolones; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; BRUCELLA; BRUCELLOSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG USE; EDITORIAL; HUMAN; IN VITRO STUDY; META ANALYSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33746643820     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01442.x     Document Type: Editorial

References (24)

1. Pappas G, Akritidis N, Bosilkovski M et al. Brucellosis. N Engl J Med 2005; 342: 2325-2336.
2. Pappas G, Akritidis N, Tsianos E. Effective treatments in the management of brucellosis. Expert Opin Pharmacother 2005; 6: 201-209.
3. Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997; 53: 245-256.
4. Pappas G, Seitaridis S, Akritidis N et al. Treatment of Brucella spondylitis: Lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004; 24: 502-507.
5. Karabay O, Sencan I, Kayas D et al. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: A randomized clinical trial. BMC Infect Dis 2004; 4: 18.
6. Bayindir Y, Sonmez E, Aladag A et al. Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: A prospective, randomized study. J Chemother 2003; 15: 466-471.
7. Kadikoylu G, Tuncer G, Bolaman Z et al. Brucellar orchitis in Innerwest Anatolia Region of Turkey. A report of 12 cases. Urol Int 2002; 69: 33-35.
8. Saltoglu N, Tasova Y, Inal AS et al. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J 2002; 23: 921-924.
9. Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1999; 18: 535-538.
10. Aygen B, Doganay M, Sumerkan B et al. Clinical manifestations, complications, and treatment of brucellosis: A retrospective evaluation of 480 patients. Med Malad Infect 2002; 32: 485-493.
11. al-Sibai MB, Halim MA, el-Shaker MM et al. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother 1992; 36: 150-152.
12. Lang R, Raz R, Sacks T et al. Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis. J Antimicrob Chemother 1990; 26: 841-846.
13. Khuri-Bulos N, Shaker K. Relapse of brucellosis following ofloxacin therapy. J Infect 1991; 22: 302-303.
14. Akalin HE, Unal S, Gur D et al. Ofloxacin in the treatment of brucellosis. In: Proceedings of the 3rd International Symposium on Quinolones, Vancouver, 1990; 326-328.
15. Akova M, Uzun O, Akalin HE et al. Quinolones in treatment of human brucellosis: Comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831-1834.
16. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM et al. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 194-195.
17. Garcia-Rodriguez JA, Garcia Sanchez JE, Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother 1991; 35: 756-759.
18. Rolain JM, Maurin M, Raoult D. Bactericidal effect of antibiotics on Bartonella and Brucella spp. clinical implications. J Antimicrob Chemother 2000; 46: 811-814.
19. Shasha B, Lang R, Rubinstein E. Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin. Antimicrob Agents Chemother 1992; 36: 973-976.
20. Rubinstein E, Lang R, Shasha B et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35: 1925-1927.
21. Al Dahouk S, Hagen RM, Nockler T et al. Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. Chemotherapy 2005; 51: 352-356.
22. Akova M, Gur D, Livermore DM et al. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999; 43: 1298-1300.
23. Qadri SM, Akhtar M, Ueno Y et al. Susceptibility of Brucella melitensis to fluoroquinolones. Drugs Exp Clin Res 1989; 15: 483-485.
24. Braibant M, Guilloteau L, Zygmunt MS. Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family. Antimicrob Agents Chemother 2002; 46: 3050-3053.